Khaled Musallam on The Lancet Haematology Podcast: Your ASH25 Roadmap
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared on reposted from The Lancet Hematology on LinkedIn:
”Check out this podcast from The Lancet Haematology to help you plan your ASH25, we give an overview of key novelties to look out for across various sessions!”
Qutoing The Lancet Hematology‘s post:
”Are you planning to attend ASH25 in Orlando?
There’s no better way to get a sneak peek at the exciting content than hearing experts share their insights firsthand.
In our latest special episode of In Conversation With, a roundtable of leading classical and malignant haematology thought leaders — Khaled Musallam, Bethany Samuelson Bannow, Mohamad Mohty, David Sallman, and Anna Sureda Balari — preview the most anticipated ASH25 sessions and their expectations for the upcoming congress.
They discuss practical implications for clinicians, researchers, and trainees, and offer takeaways to maximise your time at the meeting.
Key areas covered:
- Thalassaemia and sickle cell disease
- Thrombosis and bleeding disorders
- Multiple myeloma
- Myeloid neoplasms
- Cellular therapies, stem-cell transplantation, and lymphoma
Tune in now; search The Lancet Haematology wherever you get your podcasts.
If you’re attending ASH25 or following from afar, please share with colleagues preparing for the meeting!
Don’t forget to hit subscribe to stay ahead with the latest in haematology!”
Find the full coverage of ASH25 in Hemostasis Today.
-
Jan 22, 2026, 15:36We Must Roll Up Our Sleeves And Help: José Antonio García Erce on Plasma Donation
-
Jan 22, 2026, 15:25Nita Radhakrishnan on Challenges In Congenital Afibrinogenemia
-
Jan 22, 2026, 15:10Jin Q Gives a Summary of 2025’s Most Impactful Cell and Gene Therapy Milestones
-
Jan 22, 2026, 14:57Nirav Dhanesha on CD14 Acting As A Functional Driver of DVT
-
Jan 22, 2026, 11:41Jamilla Goedegebuur and Colleagues on VTE Management in Case of PAD
-
Jan 22, 2026, 11:28Abdulrahman Katib on API-CAT Trial’s Evaluation of Apixaban Dosing
-
Jan 22, 2026, 11:19Bruno Odisio: Ablation Margins Are Software-Dependent
-
Jan 22, 2026, 10:38Pedro Perez: The VTE Market Is Clearly Entering Its Next Phase
-
Jan 22, 2026, 10:29Marvin Garcia Reyes Presents a Case of Aorto-Visceral and Aorto-Iliac Thrombosis